BidaskClub cut shares of Pieris Pharmaceuticals (NASDAQ:PIRS) from a strong-buy rating to a buy rating in a research report report published on Saturday, February 17th.
PIRS has been the topic of several other research reports. ValuEngine cut Pieris Pharmaceuticals from a hold rating to a sell rating in a research note on Friday, December 1st. HC Wainwright restated a buy rating and issued a $9.00 target price on shares of Pieris Pharmaceuticals in a research note on Friday, November 10th. Finally, William Blair initiated coverage on Pieris Pharmaceuticals in a research note on Wednesday, January 17th. They issued an outperform rating on the stock. One research analyst has rated the stock with a hold rating and five have issued a buy rating to the company. The company presently has a consensus rating of Buy and a consensus target price of $10.00.
Pieris Pharmaceuticals (PIRS) traded down $0.28 during midday trading on Friday, reaching $7.27. The company’s stock had a trading volume of 840,075 shares, compared to its average volume of 1,170,000. The company has a market cap of $325.65, a PE ratio of -9.96 and a beta of -66.74. Pieris Pharmaceuticals has a 12-month low of $2.26 and a 12-month high of $9.75.
Institutional investors have recently made changes to their positions in the company. Arrowstreet Capital Limited Partnership bought a new stake in shares of Pieris Pharmaceuticals during the 4th quarter worth approximately $3,370,000. Teachers Advisors LLC bought a new stake in shares of Pieris Pharmaceuticals during the 2nd quarter worth approximately $308,000. JPMorgan Chase & Co. bought a new stake in shares of Pieris Pharmaceuticals during the 3rd quarter worth approximately $600,000. First Quadrant L P CA bought a new stake in shares of Pieris Pharmaceuticals during the 3rd quarter worth approximately $473,000. Finally, Creative Planning increased its holdings in shares of Pieris Pharmaceuticals by 18.2% during the 4th quarter. Creative Planning now owns 78,025 shares of the biotechnology company’s stock worth $589,000 after acquiring an additional 12,000 shares during the last quarter. Institutional investors own 47.19% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: “Pieris Pharmaceuticals (NASDAQ:PIRS) Rating Lowered to Buy at BidaskClub” was first reported by StockNewsTimes and is owned by of StockNewsTimes. If you are accessing this piece of content on another publication, it was illegally copied and reposted in violation of US & international copyright and trademark laws. The legal version of this piece of content can be viewed at https://stocknewstimes.com/2018/03/14/pieris-pharmaceuticals-pirs-downgraded-by-bidaskclub.html.
About Pieris Pharmaceuticals
Pieris Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company’s pipeline includes immuno-oncology multi-specifics tailored for the tumor micro-environment, an inhaled Anticalin to treat uncontrolled asthma and a half-life-optimized Anticalin to treat anemia. Its Anticalins proteins are a class of low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins typically found in blood plasma and other bodily fluids.
Receive News & Ratings for Pieris Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pieris Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.